接受甲氨蝶呤和生物制剂治疗的银屑病患者接种COVID-19疫苗后体液和细胞免疫减弱:一项队列研究
这项前瞻性队列研究纳入123例接受甲氨蝶呤或生物制剂治疗的银屑病患者和226例对照,仅考察按标准间隔接种的mRNA COVID-19疫苗。结果显示抗TNF治疗与较低的IgG水平相关(β=-0.82,95%CI -1.38至-0.25;P=0.001),抗TNF组中和指数中位数低于对照组,细胞反应数值上最低,提示抗TNF治疗影响mRNA疫苗接种后的免疫,但临床意义未知。
要点
- 抗TNF治疗与接种后6个月较低的IgG应答比例和IgG水平相关(β=-0.82,95%CI -1.38至-0.25;P=0.001)。
- 抗TNF组中和指数中位数为50%抑制(IQR 37-89),低于对照组的98%抑制(IQR 96-99),P<0.001。
- 抗TNF组细胞反应数值上最低;作者结论称临床意义未知。
核心结论
- 抗TNF治疗影响银屑病患者对mRNA COVID-19疫苗的免疫应答,导致体液和细胞免疫标志物更快减弱,但临床意义未知。
研究设计与样本
- 前瞻性队列研究,纳入123例接受甲氨蝶呤或生物制剂治疗的银屑病患者和226例对照,仅研究按标准间隔接种的mRNA COVID-19疫苗。
主要发现
- 接种后6个月,接受抗TNF治疗的患者中IgG应答者比例低于对照组。
- 抗TNF治疗与较低的IgG水平相关(β=-0.82,95%CI -1.38至-0.25;P=0.001)。
- 抗TNF组中和指数中位数为50%抑制(IQR 37-89),对照组为98%抑制(IQR 96-99),P<0.001。
- 细胞反应在抗TNF组数值上最低。
关键数值与推荐
- 免疫标志物包括SARS-CoV-2刺突糖蛋白特异性IgG和IgA、中和能力以及T细胞经SARS-CoV-2刺突糖蛋白肽段刺激后的干扰素-γ释放。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: mRNA-based COVID-19 vaccines have short- and long-term efficacy in healthy individuals, but their efficacy in patients with psoriasis receiving immunomodulatory therapy is less studied. OBJECTIVES: To investigate long-term immunity after COVID-19 vaccination in patients with psoriasis receiving immunomodulatory therapy. METHODS: A prospective cohort study including patients (n = 123) with psoriasis receiving methotrexate (MTX) or biologics and controls (n = 226). Only mRNA-based COVID-19 vaccines administered with standard intervals between doses were investigated. Markers of immunity included SARS-CoV-2 spike glycoprotein-specific IgG and IgA, neutralizing capacity, and interferon-γ release from T cells stimulated with peptides of the SARS-CoV-2 spike glycoprotein. RESULTS: The proportion of IgG responders was lower 6 months after vaccination in patients receiving anti-tumour necrosis factor (TNF) treatment compared with controls. Anti-TNF treatment was associated with lower IgG levels (β = -0.82, 95% confidence interval -1.38 to -0.25; P = 0.001). The median neutralizing index was lower in the anti-TNF group [50% inhibition (interquartile range [IQR] 37-89)] compared with controls [98% inhibition (IQR 96-99)]; P < 0.001. Cellular responses were numerically lowest in the anti-TNF group. CONCLUSIONS: Treatment with anti-TNF has an impact on the immunity elicited by mRNA-based COVID-19 vaccination in patients with psoriasis, resulting in a faster waning of humoral and cellular markers of immunity; however, the clinical implications are unknown.
引用
- Kvist-Hansen A, Pérez-Alós L, Al-Sofi RF, et al. Waning humoral and cellular immunity after COVID-19 vaccination in patients with psoriasis treated with methotrexate and biologics: a cohort study. Br J Dermatol. 2023. PMID: 36703193. doi:10.1093/bjd/ljad023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。